EGFR mutation

What it is

EGFR mutation is a change in the epidermal growth factor receptor (EGFR) gene, most often tested in non-small cell lung cancer (NSCLC) to guide targeted treatment. The most important practical fact is that the two common sensitising EGFR mutations are exon 19 deletions and the exon 21 L858R mutation, and these are the main changes linked to benefit from EGFR tyrosine kinase inhibitors (TKIs).

EGFR is a gene that helps control cell growth and survival. When certain mutations occur in a cancer cell, the EGFR protein can become overactive, sending continuous growth signals. In lung adenocarcinoma, this can make the cancer more likely to respond to drugs that block EGFR signaling.

In clinical practice, people often say "EGFR mutation" when they mean both the biomarker itself and the test used to detect it. Testing is usually done on tumour tissue from a biopsy or surgery specimen, but it can also be done on blood using circulating tumour DNA, often called a liquid biopsy. A negative blood test does not always rule out an EGFR mutation, because some tumours shed very little DNA into the bloodstream.

EGFR mutation testing matters because it helps doctors choose between targeted therapy, chemotherapy, immunotherapy combinations, or other treatment plans. In India, major cancer centres routinely include EGFR in molecular work-up for advanced non-squamous NSCLC when feasible, because the result can directly change first-line treatment.

How it works

EGFR encodes a receptor tyrosine kinase on the cell surface. Under normal conditions, the receptor is activated by growth factors and then triggers downstream pathways involved in cell division, survival, and repair. Certain mutations make the receptor active even without normal signaling.

This is why EGFR mutations are called predictive biomarkers. They do not just describe the cancer; they help predict whether a patient is likely to benefit from EGFR-targeted drugs.

Common clinically relevant EGFR mutation groups include:

Mutation type	Typical significance
Exon 19 deletion	Usually predicts sensitivity to EGFR TKIs
Exon 21 L858R	Usually predicts sensitivity to EGFR TKIs
Exon 20 insertion	Often associated with reduced benefit from older EGFR TKIs
T790M	Common acquired resistance mutation after earlier-generation EGFR TKIs

Not every EGFR mutation behaves the same way. Some are clearly "sensitising" mutations, meaning they are linked to response to EGFR inhibitors. Others are resistance mutations or uncommon variants with less certain treatment implications.

Evidence and uses

The strongest evidence for EGFR mutation testing is in advanced NSCLC, especially adenocarcinoma. Reviews and evidence assessments have found that somatic EGFR mutations are among the most established biomarkers for selecting EGFR-targeting therapy in this setting.

Patients whose tumours carry sensitising EGFR mutations are more likely to respond to EGFR TKIs than patients whose tumours do not have these mutations. This has changed standard care worldwide. Over time, treatment has also evolved from first-generation and second-generation TKIs to newer agents in many settings, but the basic role of testing remains the same: identify whether the cancer is driven by EGFR.

EGFR mutation status can also have prognostic associations in some studies, but its main clinical value is treatment selection, not prognosis alone. Evidence in resected early-stage disease is more nuanced than in advanced disease, and the meaning of some uncommon mutations is still being studied.

Testing may be used at more than one time point:

1. At diagnosis of advanced NSCLC to decide first-line therapy.
2. At progression on EGFR-targeted treatment to look for resistance mutations such as T790M.
3. Sometimes after surgery or in earlier-stage disease, depending on treatment planning and local protocols.

The amount of mutant DNA may also matter. Some studies suggest that mutation abundance or allele frequency could relate to treatment response, but this is not yet a simple stand-alone decision tool in routine care.

Diagnosis / how it's measured

EGFR mutation testing is a molecular pathology test, not a scan or routine blood count. The sample can come from:

• Tumour tissue from biopsy or surgery
• Cytology samples in some cases
• Blood plasma for liquid biopsy

Common laboratory methods include PCR-based assays and next-generation sequencing (NGS). The exact method depends on the lab, the amount of tissue available, cost, turnaround time, and whether the doctor wants to test only EGFR or a broader panel of cancer genes.

A typical report may include:

• Whether an EGFR mutation was found
• The exact exon and variant, such as exon 19 deletion or L858R
• Whether the result is from tissue or plasma
• Test limitations, such as low tumour content or low DNA yield

Important interpretation points:

Result	What it usually means
Positive for sensitising EGFR mutation	Targeted EGFR therapy may be appropriate
Positive for resistance mutation	May explain treatment failure and guide next steps
Negative on tissue	No EGFR mutation detected in the tested sample
Negative on liquid biopsy	Could be truly negative or falsely negative because of low tumour DNA shedding

Because sampling matters, a negative result does not always end the discussion. If suspicion remains high, doctors may recommend repeat biopsy, broader genomic testing, or tissue testing after a negative plasma result.

When to see a clinician

Ask your oncologist or pulmonologist about EGFR mutation testing if you or a family member has been diagnosed with non-small cell lung cancer, especially adenocarcinoma or advanced non-squamous disease. It is most urgent before starting systemic treatment, because the result may change the first treatment choice.

You should also ask about repeat molecular testing if the cancer grows after an EGFR-targeted drug. Resistance mutations can emerge over time, and a new test may help guide the next line of therapy.

If you have a pathology report that mentions "insufficient tissue," "QNS" (quantity not sufficient), or a negative liquid biopsy with no tissue confirmation, discuss whether another sample is needed. These are common practical issues, not unusual failures.

Limitations and open questions

EGFR mutation testing is highly useful, but it has limits. A test result depends on the quality of the sample, the sensitivity of the assay, and whether the sampled tissue reflects the whole tumour. Cancers can be heterogeneous, meaning different areas may carry different mutations.

Not all EGFR mutations have the same treatment implications. Common sensitising mutations are well studied, but uncommon variants may have less certain significance. Exon 20 insertions are a good example of a group that behaves differently from classic sensitising mutations.

Liquid biopsy is convenient and less invasive, but false-negative results can occur. Tissue testing is still important when blood testing is negative or inconclusive.

Another open question is how best to use mutation quantity, co-mutations, and serial testing over time. Evidence suggests these factors may affect response and resistance, but routine interpretation is still evolving. Patients should review results with an oncologist and, when possible, a molecular tumour board or pathology team familiar with lung cancer biomarkers.